Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
1 hedge funds and large institutions have $0 invested in Hepion Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 4 closing their positions.
75% less funds holding
Funds holding: 4 → 1 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
100% less capital invested
Capital invested by funds: $1.39K → $0 (-$1.39K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$1.39K |
HEPA Hedge Fund Activity: Q3 2025 in Review
1 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2025, worth a combined $0 — down 100% from $1.39K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of HEPA and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was XTX Topco, exiting entirely with an estimated $1.39K sold.
- 1 institutional investor held Hepion Pharmaceuticals (HEPA) as of Q3 2025, down from 4 in Q2 2025.
- Funds reported $0 of Hepion Pharmaceuticals stock for Q3 2025, down 100% quarter-over-quarter.
- 1 fund opened new Hepion Pharmaceuticals positions in Q3 2025 and 4 closed out, a net change of -3 holders.
- The largest Hepion Pharmaceuticals seller in Q3 2025 was XTX Topco, an estimated $1.39K sold.
Based on aggregated 13F filings for Q3 2025.